ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > B7-2

B7-2

概要

Name:Cluster of differentiation 86
Target Synonym:FUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Antigen,LAB72,B7-2,B7.2,B7-2 Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CD6-H82F5-Cell-based assay
 B7-2 FACS

Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).

CD6-H82F5-Cell-based assay
 B7-2 FACS

FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).

CD6-C5254-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD6-H5223-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 6.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

カスタマーレビュー

Synonym Name

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix United States Rejection of renal transplantation Bristol-Myers Squibb Pharma Eeig 2011-06-15 Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic Details
Abatacept BMS-188667SC; ONO-4164; BMS-188667; ONO-4164SC Approved Bristol-Myers Squibb Company Orencia, 恩瑞舒 United States Arthritis, Rheumatoid Bristol-Myers Squibb Company 2005-12-23 Colitis, Ulcerative; Arthritis; Common Variable Immunodeficiency; Uveitis; Cardiovascular Diseases; Asthma; Arthritis, Psoriatic; Sjogren-Larsson Syndrome; Urticaria; Scleroderma, Diffuse; Psoriasis; Takayasu Arteritis; Glomerulosclerosis, Focal Segmental; Anemia, Aplastic; Lupus Erythematosus, Systemic; Shwachman-Diamond Syndrome; Lung Diseases, Interstitial; Multiple Sclerosis; Nephrotic Syndrome; Muscular Diseases; Eye Diseases; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Arthralgia; Myocarditis; Leukocyte-Adhesion Deficiency Syndrome; Inflammation; Vitiligo; Anemia, Sickle Cell; Thrombasthenia; Kostmann Syndrome; Crohn Disease; Behcet Syndrome; Graft vs Host Disease; Polychondritis, Relapsing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Polymyositis; Wiskott-Aldrich Syndrome; Hematologic Diseases; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Alopecia Areata; Myositis; Dermatomyositis; Giant Cell Arteritis; Immunoglobulin G4 Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd Carcinoma, Non-Small-Cell Lung Details
ORCA-010 ORCA-010 Phase 2 Clinical Orca Therapeutics Bv Prostatic Neoplasms Details
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) Phase 1 Clinical Beijing Vdjbio Co Ltd Arthritis, Rheumatoid Details

This web search service is supported by Google Inc.

totopphone